Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02993068 |
Recruitment Status :
Recruiting
First Posted : December 14, 2016
Last Update Posted : July 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
BARD1 Gene Mutation BRCA1 Gene Mutation BRCA2 Gene Mutation BRIP1 Gene Mutation Estrogen Receptor Negative HER2/Neu Negative MLH1 Gene Mutation MSH2 Gene Mutation MSH6 Gene Mutation PALB2 Gene Mutation PMS2 Gene Mutation Progesterone Receptor Negative RAD51C Gene Mutation RAD51D Gene Mutation Triple-Negative Breast Carcinoma | Other: Educational Intervention Other: Genetic Counseling Other: Laboratory Biomarker Analysis Other: Questionnaire Administration | Not Applicable |
PRIMARY OBJECTIVES:
I. To test the effects of online genetic education versus telephone genetic counseling on cancer-risk distress.
SECONDARY OBJECTIVES:
I. To test the effects of online genetic education versus telephone genetic counseling on testing completion rates.
II. To evaluate the role of psychological and social variables in women's reactions to genetic testing for ovarian cancer risk with variable education strategies.
III. To consider the effects of variations of genetic education/counseling on genetic knowledge, satisfaction with the decision to undergo testing, and family communication.
OUTLINE: Patients are randomized into 1 of 4 arms.
ARM A: Patients watch genetic testing online educational video and receive genetic testing online test results report.
ARM B: Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
ARM C: Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
ARM D: Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 5200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) |
Actual Study Start Date : | April 18, 2017 |
Estimated Primary Completion Date : | April 18, 2024 |
Estimated Study Completion Date : | April 18, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm A (online education)
Patients watch genetic testing online educational video and receive genetic testing online test results report.
|
Other: Educational Intervention
Watch genetic testing online educational video
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Other: Questionnaire Administration Ancillary studies |
Experimental: Arm B (online education, post telephone counseling)
Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
|
Other: Educational Intervention
Watch genetic testing online educational video
Other Names:
Other: Genetic Counseling Receive post-telephone genetic counseling Other: Laboratory Biomarker Analysis Correlative studies Other: Questionnaire Administration Ancillary studies |
Active Comparator: Arm C (online education, pre- and post-telephone counselling)
Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
|
Other: Educational Intervention
Watch genetic testing online educational video
Other Names:
Other: Genetic Counseling Receive post-telephone genetic counseling Other: Genetic Counseling Receive pre-telephone genetic counseling Other: Laboratory Biomarker Analysis Correlative studies Other: Questionnaire Administration Ancillary studies |
Experimental: Arm D (online education, pre-telephone counseling)
Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
|
Other: Educational Intervention
Watch genetic testing online educational video
Other Names:
Other: Genetic Counseling Receive pre-telephone genetic counseling Other: Laboratory Biomarker Analysis Correlative studies Other: Questionnaire Administration Ancillary studies |
- Mean cancer stress scores [ Time Frame: Up to 4 years ]
Mean cancer stress scores are measured on the Impact of Events Scale (IES), a 15-item self-report measure that assesses subjective distress caused by traumatic events, which may include a positive genetic test result.There are two subscales, Intrusion and Avoidance, used to calculate a total. The range for Intrusion is 0-35 and the range for Avoidance is 0-40. The range of the total score is 0-75. Higher scores reflect more stressful impact, and therefore, a worse outcome.
Subscales are summed to compute the total score.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 30 or older. Note: Participants must meet each of Criteria 1-4.
- Have access to a healthcare provider and be willing to share genetic results with that provider
- Have at least one ovary
- Have a valid United States mailing address for receipt of saliva kit
- Participants must meet any one of the following 6 criteria:
- Diagnosed with breast cancer at age 45 or younger
- Diagnosed with triple negative (negative for estrogen receptor, progesterone receptor and not human epidermal growth factor receptor 2 [Her2] amplified) breast cancer at 60 or younger
- Have one blood relative with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, or PMS2
- Have one relative with ovarian cancer
- Have at least 2 relatives with breast cancer on the same side of the family, one of which is =< 50 years of age
- Have one male relative with breast cancer
Exclusion Criteria:
- Personal history of ovarian cancer
- Unable to read, speak, and understand English
- Unable to provide informed consent
- Unwilling to complete baseline and follow-up questionnaires
- Unable to access the internet
- Previous genetic testing or counseling regarding cancer risk
- Previous bone marrow transplant
- Previous blood transfusion (7 days prior to genetic testing)
- Active hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02993068
Contact: Karen H. Lu, MD | 713-745-7877 | magenta@mdanderson.org |
United States, Texas | |
M D Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Karen H. Lu 713-745-8902 | |
Principal Investigator: Karen H. Lu | |
United States, Washington | |
University of Washington Medical Center | Recruiting |
Seattle, Washington, United States, 98195 | |
Contact: Elizabeth M. Swisher swishere@u.washington.edu | |
Principal Investigator: Elizabeth M. Swisher |
Principal Investigator: | Karen H Lu | M.D. Anderson Cancer Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT02993068 |
Other Study ID Numbers: |
2016-0298 NCI-2017-01600 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2016-0298 ( Other Identifier: M D Anderson Cancer Center ) |
First Posted: | December 14, 2016 Key Record Dates |
Last Update Posted: | July 21, 2023 |
Last Verified: | July 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |